Factor Xa Inhibitors - McMaster Experts

subject area of

2 Mechanisms of action of low molecular weight heparins and heparinoids Academic Article
2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Academic Article
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer Academic Article
2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants Academic Article
4 Clinical potential of low molecular weight heparins Academic Article
A Replacement for Warfarin Academic Article
A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system Academic Article
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery Academic Article
A new antithrombotic strategy, the selective inhibition of coagulation factors, and its importance to the orthopedic specialist. Academic Article
A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury Academic Article
A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation Academic Article
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers Academic Article
A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin Academic Article
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study Academic Article
A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2) Academic Article
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) Academic Article
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer Academic Article
Accumulating data on rivaroxaban for venous thromboembolism in clinical practice Academic Article
Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial Academic Article
Activated Clotting Time to Guide Heparin Dosing in Non–ST-Segment–Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Academic Article
Acute management of bleeding in patients on novel oral anticoagulants Academic Article
Advances in Antithrombotic Therapy: Novel Agents Academic Article
Advances in the management of venous thromboembolism. Academic Article
Advantages and limitations of the new anticoagulants Academic Article
An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition Academic Article
An assay to measure levels of factor Xa inhibitors in blood and plasma Academic Article
Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study Academic Article
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors Academic Article
Andexanet Alfa for Bleeding with Factor Xa Inhibitors Academic Article
Andexanet Alfa for Factor Xa Inhibitor Reversal Academic Article
Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban Academic Article
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity Academic Article
Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence Academic Article
Andexanet alfa for the treatment of hemorrhage Academic Article
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis Academic Article
Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients Academic Article
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Academic Article
Anticoagulant Mechanisms of Orgaran (Org 10172) and Its Fraction with High Affinity to Antithrombin III (Org 10849) Academic Article
Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis Academic Article
Anticoagulants in heart disease: current status and perspectives Academic Article
Anticoagulation Therapy in Children Academic Article
Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes Academic Article
Anticoagulation for Mechanical Heart Valves Academic Article
Antithrombotic Agents Academic Article
Antithrombotic Therapy in Neonates and Children Academic Article
Apixaban for Extended Treatment of Venous Thromboembolism Academic Article
Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?—A Systematic Review Academic Article
Apixaban in Acute Coronary Syndromes Academic Article
Apixaban in Patients with Atrial Fibrillation Academic Article
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer Academic Article
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement Academic Article
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Academic Article
Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials Academic Article
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty Academic Article
Assays for Measuring Rivaroxaban: Their Suitability and Limitations Academic Article
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes Academic Article
Barriers and facilitators to optimal oral anticoagulant management: a scoping review Academic Article
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin Academic Article
Beyond Unfractionated Heparin and Warfarin Academic Article
Bleeding Complications and Management on anticoagulant therapy Academic Article
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design Academic Article
Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery Academic Article
COMPASS for Vascular Surgeons Academic Article
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF Academic Article
Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial Academic Article
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source Academic Article
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial Academic Article
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials Academic Article
Circulating heparin‐like anticoagulants: Case report and review of literature Academic Article
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study Academic Article
Clinical implications of reversal agents for direct oral anticoagulants Academic Article
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist Academic Article
Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients Academic Article
Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis Academic Article
Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study Academic Article
Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance. Academic Article
Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study Academic Article
Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy Academic Article
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)‐5 trial Academic Article
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents Academic Article
Dabigatran: ready for prime time? Academic Article
Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency Academic Article
Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH Academic Article
Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syndromes with a planned early invasive strategy Academic Article
Design of the rivaroxaban for heparin-induced thrombocytopenia study Academic Article
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation Academic Article
Direct Factor Xa and direct thrombin inhibitors: a clinical trial update. Academic Article
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies Academic Article
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Academic Article
Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis Academic Article
Direct oral anticoagulants: evidence and unresolved issues Academic Article
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism Academic Article
Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events Academic Article
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease Academic Article
Edoxaban for the Treatment of Venous Thromboembolism in Patients with Cancer Academic Article
Edoxaban for treatment of venous thromboembolism in patients with cancer Academic Article
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial Academic Article
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial Academic Article
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty Academic Article
Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study Academic Article
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism Academic Article
Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state Academic Article
Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism Academic Article
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1 Academic Article
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis Academic Article
Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial Academic Article
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial Academic Article
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease Academic Article
Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction Academic Article
Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor–associated major bleeding Academic Article
Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin Academic Article
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients Academic Article
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study Academic Article
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry Academic Article
External applicability of the COMPASS trial: the Western Denmark Heart Registry Academic Article
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis Academic Article
Factor Xa and thrombin as targets for new oral anticoagulants Academic Article
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism Academic Article
Fondaparinux Reduces Long-term Risk of Venous Thromboembolism After Surgery for Hip Fractur Academic Article
Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6 Academic Article
Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) – Bridging the River Coumarin Academic Article
Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy Academic Article
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial Academic Article
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source Academic Article
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors Academic Article
Gastrointestinal Bleeding With Edoxaban Versus Warfarin Academic Article
Global Prospective Safety Analysis of Rivaroxaban Academic Article
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors Academic Article
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease Academic Article
Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding Academic Article
Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care Academic Article
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source Academic Article
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? Academic Article
How can we reverse bleeding in patients on direct oral anticoagulants? Academic Article
How to use unfractionated heparin to treat neonatal thrombosis in clinical practice Academic Article
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban Academic Article
Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE Academic Article
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial Academic Article
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy Academic Article
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study Academic Article
Incidence of intracranial bleeding in anticoagulated patients with minor head injury: a systematic review and meta-analysis of prospective studies Academic Article
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation Academic Article
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome Academic Article
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes Academic Article
Influence of the duration of fondaparinux (Arixtra®) prophylaxis in preventing venous thromboembolism following major orthopedic surgery Academic Article
Inhibition of Fibrin-Bound Thrombin by a Covalent Antithrombin-Heparin Complex Academic Article
Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex Academic Article
Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome Academic Article
Interaction of low molecular weight heparin with ketorolac Academic Article
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy Academic Article
Investigation of the Anticoagulant Mechanisms of a Covalent Antithrombin-Heparin Complex Academic Article
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48 Academic Article
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants Academic Article
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation Academic Article
Laboratory monitoring of low‐molecular‐weight heparin therapy Academic Article
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin Academic Article
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial Academic Article
Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES Academic Article
Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels Academic Article
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials Academic Article
Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS Academic Article
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial Academic Article
Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review Academic Article
Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study Academic Article
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease Academic Article
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin Academic Article
Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor Academic Article
Management of Anticoagulation Therapy in Patients With Thromboembolism in the Context of Renal Dysfunction Academic Article
Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis Academic Article
Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex Academic Article
Mechanisms Responsible for Catalysis of the Inhibition of Factor Xa or Thrombin by Antithrombin Using a Covalent Antithrombin-Heparin Complex Academic Article
Meeting the Unmet Needs in Anticoagulant Therapy Academic Article
Monitoring Unfractionated Heparin (UFH) therapy: Which Anti Factor Xa assay is appropriate? Academic Article
Monitoring and reversal of direct oral anticoagulants Academic Article
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease Academic Article
Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials Academic Article
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank Academic Article
New Anticoagulants for Atrial Fibrillation Academic Article
New Antithrombotic Drugs: Potential for Use in Oncology Academic Article
New aspects on treatment modalities for thromboembolic episodes Academic Article
New oral anticoagulants in atrial fibrillation Academic Article
New oral anticoagulants in development Academic Article
New oral anticoagulants: not quite there yet Academic Article
New oral anticoagulants: which one should my patient use? Academic Article
New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010 Academic Article
North America anticoagulation forum guidance on reversal of direct oral anticoagulants Academic Article
Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism Academic Article
Novel oral anticoagulants and reversal agents: Considerations for clinical development Academic Article
Novel paediatric anticoagulants: a review of the current literature Academic Article
Oral Anticoagulant Therapy Academic Article
Oral Apixaban for the Treatment of Acute Venous Thromboembolism Academic Article
Oral Direct Factor Xa Inhibitors Academic Article
Oral Rivaroxaban for Symptomatic Venous Thromboembolism Academic Article
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial Academic Article
Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis Academic Article
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement Academic Article
Oral factor Xa inhibitors and risk of subdural hematoma Academic Article
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement Academic Article
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases Academic Article
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials Academic Article
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study Academic Article
Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Academic Article
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study Academic Article
Overview of the New Oral Anticoagulants Academic Article
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry Academic Article
Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS ₂ Score: Insights From the BRAIN-AF Trial Academic Article
Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for practice Academic Article
Pentasaccharides Academic Article
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy Academic Article
Pharmacokinetic Profile of a Low-Molecular Weight Heparin (Reviparin) in Pregnant Patients Conference Paper
Pharmacologic tools to reduce bleeding in surgery. Academic Article
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome Academic Article
Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose Academic Article
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment Academic Article
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery Academic Article
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients Academic Article
Potential Risk Factors Contributing to Development of Venous Thromboembolism for Total Knee Replacements Patients Prophylaxed With Rivaroxaban: A Retrospective Case-Control Study Academic Article
Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants Academic Article
Preclinical differentiation of low molecular weight heparins. Academic Article
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study Academic Article
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial Academic Article
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial Academic Article
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX‐2) Academic Article
Probable fondaparinux-associated bullous hemorrhagic dermatosis Academic Article
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism Academic Article
Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins Academic Article
Prophylactically equivalent doses of Enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent Academic Article
Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex Academic Article
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study Academic Article
Prothrombin Complex Concentrates for Intracranial Hemorrhage on Factor Xa Inhibitors Academic Article
Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study Academic Article
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome Academic Article
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation Academic Article
Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis Academic Article
Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention Academic Article
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation Academic Article
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD) Academic Article
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial Academic Article
Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS Academic Article
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation Academic Article
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study Academic Article
Reduction of thrombus size in murine models of thrombosis following administration of recombinant α1-proteinase inhibitor mutant proteins Academic Article
Reply Academic Article
Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban Academic Article
Response to “Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban” Academic Article
Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients Academic Article
Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding Academic Article
Reversal of target-specific oral anticoagulants Academic Article
Reversing Anticoagulant Therapy Academic Article
Review: In renal impairment, apixaban reduces, or does not increase, bleeding compared with other anticoagulants Academic Article
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial Academic Article
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban Academic Article
Risk of recurrent venous thromboembolism according to baseline risk factor profiles Academic Article
Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis Academic Article
Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial Academic Article
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Academic Article
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial Academic Article
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease Academic Article
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease Academic Article
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization Academic Article
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios Academic Article
Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation Academic Article
Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro Academic Article
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial Academic Article
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline Academic Article
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source Academic Article
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness Academic Article
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer Academic Article
Rivaroxaban for prevention and treatment of venous thromboembolism Academic Article
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease Academic Article
Rivaroxaban for treatment of HIT: A riveting first experience Academic Article
Rivaroxaban for treatment of suspected or confirmed heparin‐induced thrombocytopenia study Academic Article
Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment Academic Article
Rivaroxaban in Peripheral Artery Disease after Revascularization Academic Article
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation Academic Article
Rivaroxaban in Stable Cardiovascular Disease Academic Article
Rivaroxaban in treatment refractory heparin-induced thrombocytopenia Academic Article
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism Academic Article
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial Academic Article
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition Academic Article
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers Academic Article
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty Academic Article
Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy Academic Article
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial Academic Article
Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial Academic Article
Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study Academic Article
Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial Academic Article
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease Academic Article
Rivaroxaban with or without aspirin for prevention of cardiovascular disease Academic Article
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial Academic Article
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Academic Article
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion Academic Article
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease Academic Article
SR123781A: A New Once-Daily Synthetic Oligosaccharide Anticoagulant for Thromboprophylaxis After Total Hip Replacement Surgery Academic Article
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Academic Article
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study Academic Article
Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation Academic Article
Selective factor Xa inhibition for thromboprophylaxis Academic Article
Setting a standard for venous thromboembolism prophylaxis Academic Article
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment Academic Article
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease Academic Article
The APTT Response of Pregnant Plasma to Unfractionated Heparin Academic Article
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation Academic Article
The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War? Academic Article
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE Academic Article
The Real Decoy Academic Article
The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement Academic Article
The comparison of the pharmacokinetics of a low molecular weight heparin in the newborn and adult pig Academic Article
The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study Academic Article
The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era Academic Article
The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect Academic Article
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients Academic Article
The relationship between ex vivo anti-factor Xa levels and efficacy/safety of low molecular weight heparin. Academic Article
The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants Academic Article
Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin Academic Article
Timing of Angiography and Outcomes in High-Risk Patients With Non–ST-Segment–Elevation Myocardial Infarction Managed Invasively Academic Article
To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment Academic Article
Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding Academic Article
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies Academic Article
Treatment of bleeding complications in patients on anticoagulant therapy Academic Article
Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti‐factor Xa levels Academic Article
Urgent Need to Measure Effects of Direct Oral Anticoagulants Academic Article
Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children Academic Article
Use of selective factor Xa inhibitors in special populations. Academic Article
Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study Academic Article
Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation Academic Article
What Is the Future of Factor XI Inhibitors? Academic Article
Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation? Academic Article
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America Academic Article
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation Academic Article
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation Academic Article
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both Academic Article

Factor Xa Inhibitors Concept

Vocabulary Service

Overview

subject area of